.png){kind=icon}
.png){kind=icon}
Return
Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect
.png){kind=icon}
PRE
AI
X
H
P
DOI：10.1177/20451253261450772.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
<jats:sec>
<jats:title>Background:</jats:title>
<jats:p>The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Objectives:</jats:title>
<jats:p>To investigate whether adjunctive aripiprazole treatment can reverse amisulpride-induced prolactin (PRL) elevation.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Design:</jats:title>
<jats:p>This study was a single-arm retrospective cohort study.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>
We conducted a retrospective analysis of medical records from patients treated with amisulpride at a tertiary specialized psychiatric hospital, between June 1, 2022, and December 31, 2025, who subsequently received adjunctive aripiprazole. Data were collected via the electronic medical record system. A paired
<jats:italic toggle="yes">t</jats:italic>
-test was used to compare PRL values before (⩽7 days, PRL1) and after (⩾7 days, PRL2) aripiprazole initiation.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>
The difference between PRL1 and PRL2 was not statistically significant (mean difference = 4.115 ng/ml, 95% CI (−5.121, 13.351) ng/ml, SD = 15.284,
<jats:italic toggle="yes">p</jats:italic>
= 0.351, Cohen’s
<jats:italic toggle="yes">d</jats:italic>
= 0.269, 95% CI for
<jats:italic toggle="yes">d</jats:italic>
(−0.290, 0.818)). Stratified analyses by sex and diagnosis yielded results consistent with the main analysis across subgroups (
<jats:italic toggle="yes">p</jats:italic>
> 0.05). None of the leave-one-out analyses altered the study’s conclusions (all
<jats:italic toggle="yes">p</jats:italic>
-values > 0.05), indicating that the results were not driven by any single extreme value.
</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion:</jats:title>
<jats:p>In individuals with amisulpride-related hyperprolactinemia, this retrospective study suggests that adjunctive aripiprazole has an insignificant therapeutic effect in reversing PRL elevation. Therefore, until more comprehensive research evidence becomes available, a cautious approach should be taken in clinical practice regarding the use of adjunctive aripiprazole to reverse amisulpride-induced PRL elevation.</jats:p>
</jats:sec>
Journal
T
IF:
4
Papers:
436
Citations:
1.5K
Organization
Cited Papers